Last reviewed 2026-05-26 · How we verify

EXIPROBEN

Phase 2 active Small molecule ✓ Verified May 2026

EXIPROBEN is a exiproben drug. It is currently in Phase 2 development.

Exiproben is a small molecule that works by interacting with a specific target in the body, but its exact mechanism is unknown.

Exiproben is a small molecule with the synonyms DCH 21 FREE ACID, DCH-21 FREE ACID, and EXIPROBENE.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	EXIPROBEN
Drug class	exiproben
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine exiproben as a key that fits into a lock in the body. When it binds to its target, it can either block or enhance the activity of that target, leading to changes in the body's function. However, without knowing the target, it's difficult to predict exactly how exiproben will affect the body.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

EXIPROBEN CI brief — competitive landscape report
EXIPROBEN updates RSS · CI watch RSS

Frequently asked questions about EXIPROBEN

What is EXIPROBEN?

EXIPROBEN is a exiproben drug.

How does EXIPROBEN work?

Exiproben is a small molecule that works by interacting with a specific target in the body, but its exact mechanism is unknown.

What drug class is EXIPROBEN in?

EXIPROBEN belongs to the exiproben class. See all exiproben drugs at /class/exiproben.

What development phase is EXIPROBEN in?

EXIPROBEN is in Phase 2.

Drug class: All exiproben drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing